Delivery Order SPE2DB25D3404-SPE2DB25FUPZC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,278.42 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a delivery order valued at $4,508.41 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's extensive pharmaceutical distribution portfolio for federal medical procurement. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $8,861.23 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on September 4, 2025, with an ultimate completion date of September 5, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $21,377.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 0.5 mg tablets (30-count packaging) under a firm fixed-price contract. This non-competitive, non-set-aside delivery order was awarded on July 14, 2025, with an ultimate completion date of July 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Rexulti is an atypical antipsychotic medication used in the...
- The Defense Logistics Agency awarded a delivery order valued at $23,256.95 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. This non-set-aside award was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and represents a pharmaceutical delivery to support federal medical procurement needs. The contract is executed from AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPZCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,864.83 to AmerisourceBergen Drug Corp for the supply of Rexulti (aripiprazole) 1 mg tablets in a 30-count package. This is a firm fixed-price delivery order with no set-aside designation, awarded on August 20, 2025, and scheduled for completion by August 21, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major healthcare distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military and federal healthcare programs worldwide. Rexulti, an atypical antipsychotic medication used in treating schizophrenia and bipolar disorder, represents the type of specialty pharmaceutical product that AmerisourceBergen routinely delivers through its DLA contract portfolio to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 8/20/25 |